Unicycive Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Unicycive Therapeutics, Inc. filed a Current Report on Form 8-K concerning a change in its independent registered public accounting firm. The reported event occurred on August 28, 2023; the filing was signed and dated August 31, 2023.
The company is a Delaware corporation whose common stock trades on the Nasdaq Capital Market under the symbol UNCY. The filing does not provide operating or financial-period results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial metrics.
Material Changes
- Mayer Hoffman McCann P.C. notified the Audit Committee that it would resign as the company’s independent registered public accounting firm, effective upon the earlier of the engagement of a successor, the filing of the June 2023 Form 10-Q, or August 20, 2023.
- On August 28, 2023, the company appointed Grassi & Co. CPAs, P.C. as its new independent registered public accounting firm, subject to completion of Grassi’s client acceptance process.
- The appointment was approved by the Audit Committee of the company’s board of directors.
Guidance, Outlook, Risks, and Unusual Items
The filing contains no financial guidance or business outlook. The appointment remained subject to Grassi completing its client acceptance process, which represents the principal procedural contingency disclosed.
For the fiscal year ended December 31, 2022 and the interim period from January 1, 2023 through June 30, 2023, the company stated that neither it nor anyone acting on its behalf had consulted with Grassi regarding accounting principles, audit opinions, disagreements, or reportable events. The filing does not describe any disagreement or reportable event involving Grassi.
Investor Verification Items
- Verify completion of Grassi’s client acceptance process and its continued engagement as auditor.
- Review the June 2023 Form 10-Q and subsequent filings for any auditor disclosures, going-concern language, financial results, or liquidity updates.
- Confirm the effective date and circumstances of MHM’s resignation in the company’s related July 31, 2023 Form 8-K and subsequent filings.